TreAtments and outComes in paTients With prImary CutAneous Lymphoma
Treatments and Outcomes in Patients With Primary Cutaneous Lymphoma: a Nationwide Multi-center Prospective Study in China
Peking University First Hospital
3,000 participants
Aug 1, 2022
OBSERVATIONAL
Conditions
Summary
In order to further improve the diagnosis and treatment level of primary cutaneous lymphoma in China, the National Clinical Center for Skin and Immune Diseases established a standardized diagnosis and treatment center for primary cutaneous lymphoma to systematically and effectively understand the current treatment status of patients with primary cutaneous lymphoma, as well as the efficacy and safety of various treatment methods during practices, so as to further improve the diagnosis and treatment level of primary cutaneous lymphoma and help patients with primary cutaneous lymphoma.
Eligibility
Inclusion Criteria2
- Patients from the participatin medical centers that has passed the data review of the National Clinical Center for Skin and Immune Diseases.
- Patients with a definitive pathological diagnosis of primary cutaneous lymphoma by skin biopsy.
Exclusion Criteria2
- Patients who fail to provide informed consent form.
- Patients who cannot complete the questionnaire independently or under the guidance of investigators.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05518851